Kymera Q2 2026: KT-621 Phase 2b Enrollment Completed Early, Data by Year-End; $1.5B Cash Runway into 2029
KYMR has more than doubled off its 52-week low of $36.65.
Summary
Kymera reported Q2 2026 revenue of $65M and a net loss of $61.2M, with $1.5B in cash. The KT-621 Phase 2b trial in atopic dermatitis completed enrollment early, moving the data readout to year-end 2026. Two partnered programs triggered $65M in milestones.
Key Events · Earnings and Guidance · KYMR
-
KT-621 Phase 2b Enrollment Completed Early
The BROADEN2 trial in moderate-to-severe atopic dermatitis completed enrollment nearly six months ahead of schedule, accelerating the expected topline data readout to year-end 2026 from mid-2027.
-
Phase 3 Initiation Planned by Mid-2027
Subject to regulatory discussions, Kymera expects to start Phase 3 trials for KT-621 in atopic dermatitis by mid-2027, earlier than previously anticipated.
-
$65M in Milestone Payments Boost Revenue
Collaboration revenue of $65.0M included a $45M option exercise fee from Gilead for KT-200 and a $20M milestone from Sanofi for the first patient dosed in the KT-485 Phase 1 trial.
-
Cash Runway Extended into 2029
Kymera ended Q2 2026 with $1.5 billion in cash, cash equivalents, and investments, providing runway beyond multiple clinical inflection points.
Analysis · KYMR · Life Sciences
A pivotal quarter for Kymera: the KT-621 atopic dermatitis Phase 2b trial enrolled nearly six months ahead of schedule, pulling the topline data readout forward to year-end 2026 — a major derisking event for the lead program. Two substantial milestone payments ($45M from Gilead, $20M from Sanofi) boosted revenue to $65M, and the $1.5B cash position extends runway into 2029, well past multiple clinical inflection points. The accelerated timeline and strong balance sheet meaningfully improve the risk/reward profile ahead of the data catalyst.
At the time of this filing, KYMR was trading at $104.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $36.65 to $130.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.